The following are study notes compiled by the above PGY-5 medical oncology residents and reviewed by a staff medical oncologist. They reflect what we feel is relevant knowledge for graduating medical oncology residents preparing for their final examination. The information has not been surveyed or ratified by the Royal College.
Epidemiology
• Incidence: adenocarcinoma is increasing dramatically (?due to obesity), SCC decreasing over time. SCC comprises 90% of all esophageal cancers. -Incidence of superficial esophageal cancer is increasing, particularly in Asian countries where screening for upper digestive tract cancers is common -Similar trend in United States, attributed in part to routine endoscopic surveillance for malignancy and high-grade dysplasia in patients with Barrett's esophagus
Risk factors
• Age • Lifestyle -SCC: smoking, alcohol, betel nut chewing, N-nitroso containing foods -AdenoCA: obesity, smoking, N-nitroso foods • Hereditary: Tylosis (hyperkaratosis palms and soles of feet) -AD 17q25 for SCC • Other -SCC: Achalasia, caustic stricture, ?HPV, prior H&N SCC -AdenoCA: HP infection, Barrett's (GERD), obesity, Zollinger Ellison, prior cholecystectomy, ?drugs that relax esophageal sphincter (nitrates, BDZ)
Staging
• CT chest/abdomen/pelvis • Endoscopy/EUS: biopsy, location, T staging • PET: essential for pre-operative assessment • Differences between squamous and adenocarcinoma in staging -In SCC, stages can change depending on grade and location Ø E.g. Poor grade, upper/middle location upgraded from 1Aà1B, 1Bà2A etc.
-In adenocarcinoma, only TNM stages affect final stage.
• Upper (cervical) cancer, T4 generally difficult to resect and typically treated with chemoradiation.
• Multidisciplinary approach important Although 11 treatment related deaths occurred in the high dose arm compared w two in the standard dose arm, 7 of the 11 deaths occurred in the patients who had received 50.4 Gy or less
Conclusion
The higher RT dose did NOT increase survival or local/regional control Although there was a higher treatment related mortality rate in the pts assigned to the high dose RT arm, it did not seem to be related to the higher RT dose The standard RT dose for pts treated w concurrent 5FU and cisplatin chemo is 50.4Gy
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer (Conroy NEJM 2012)

Regimen
In Arm A (FOLFOX), patients received 6 bimonthly cycles: Oxaliplatin 85 mg/m2 d1, leucovorin 200 mg/m2 followed by 5-FU 400 mg/m2 bolus d1 then 1,600 mg/m2 46h continuous infusion The first 3 cycles were delivered concurrently with radiation therapy and the last 3 cycles were delivered adjuvantly.
In Arm B (Cisplatin/5FU), patients received 4 cycles: Cisplatin 75 mg/m2 d1 followed by 5FU 1,000 mg/m2/d ci d1-4, The first 2 cycles were delivered concurrently with radiation therapy and the last 2 cycles were delivered adjuvantly Primary Endpoint PFS There was a trend toward more toxic deaths in the cisplatin/5FU arm (6.4 vs. 1.1%, p=0.06).
Inclusion/Exclusion Criteria
Conclusion
Full treatment was delivered to 67.9% patients receiving FOLFOX and 72.2% receiving cisplatin/5FU (p=0.05). There was also no difference in treatment delay between the two arms.
Neoadjuvant chemotherapy followed by surgery Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study--JCOG9204.
(Ando JCO 2003)
Regimen
Surgery alone Vs surgery plus chemo, including 2 courses of cisplatin 80mg/m2 on d1) and FU 800mg/m2 x 5 days within 2 months after surgery Primary Endpoint DFS
Inclusion/Exclusion Criteria
Patients with localized SCC of thoracic esophagus, undergoing transthoracic esophagectomy w lymphadenectomy Size (N) 242 Results
• 5 year DFS 45% vs 55%, p=0.037
• 5 year OS rate 52 vs 61%, p=0.13 (NONSIG) Toxicity Grade 3 or 4 heme or nonheme toxicities were limited Conclusion Postop adjuvant chemo w cisplatin and FU is better able to prevent relapse in pts w esophageal cancer than surgery alone 
Size (N)
802 Results
• The survival benefit has been maintained with a hazard ratio (HR) of 0.84 (95% CI, 0.72 to 0.98; P = .03) which in absolute terms is a 5-year survival of 23.0% for CS compared with 17.1% for S.
• The treatment effect is consistent in both adenocarcinoma and squamous cell carcinoma.
• The first disease-free survival event was macroscopic residual disease from incomplete resection (R2) or no resection in 26.4% of the S group versus 14.3% of the CS P < .001. Three-year survival by type of resection was R0 42.4%, R1 was 18.0%, and R2 was 8.6%.
Conclusion
Long-term follow-up confirms that preoperative chemotherapy improves survival in operable esophageal cancer and should be considered as a standard of care. 
Regimen
Induction chemo (15 weeks) followed by surgery (arm A) Vs Chemotherapy (12 weeks) followed by chemoRT (3 weeks) followed by surgery (Arm B)
Treatment in arm A consisted of induction chemotherapy with 2.5 courses of cisplatin, fluorouracil, leucovorin (PLF). One course comprised a 6-week schedule of weekly fluorouracil (2 g/m2, 24-hour infusion) and leucovorin (500 mg/m2, 2-hour infusion) as well as biweekly cisplatin (50 mg/m2, 1-hour infusion).
Treatment of arm B consisted of 2.0 courses of the same induction chemotherapy. This was followed by 3 weeks of combined chemoradiotherapy.
Surgery was performed 3 to 4 weeks after the end of chemotherapy (arm A) or chemoradiotherapy (arm B PET non-responders (≤35% decrease in SUV -PET-NR) crossed over to alternative CT regimen during CRT (50.4Gy/28 fractions). PET responders (>35% decrease in SUV -PET-R) continued on same CT during CRT. Primary Endpoint pCR in PET-NR who crossed over to alternative chemotherapy Inclusion/Exclusion Criteria patients (pts) with resectable esophageal and gastroesophageal junction (GEJ) adenocarcinomas.
Size (N)
257 Results
• FOLFOX vs CP PET-R 57 vs 50% pCR 38 vs 10% PET-NR 30 vs 38% pCR 16 vs 15% For PET-NR who crossed over to alternative CT during CRT, pCR was 15.6%; 95% CI (0.08, 0.26).
Other Comments
Efficacy criteria were met for an improvement in pCR rates among pts who were PET-NR after induction CT and received alternative CT during CRT for esophageal and GEJ adenoca. Pts receiving induction and concurrent CP had an unexpectedly low pCR.
Adjuvant therapy
• GEJ adenocarcinoma -treated similarly to gastric adenocarcinoma (e.g. MAGIC, MacDonald protocol, ARTIST); no evidence for adjuvant therapy in SCC or upper/middle esophageal cancer.
Utility of post induction therapy PET scans -Post induction therapy FDG-PET provides info about metabolic response in the primary tumor that may be clinically useful for selection of subsequent therapy.
In particular some retrospective data suggest that post-chemo FDG-PET scan may serve to identify those pts for whom surgery might be avoided -However, others have failed to find a correlation between the postchemoRT SUV on PET and pathologic response -Thus, these data need to be confirmed and validated in a prospective trial before PETdirected therapy for esophageal cancer can be considered a standard approach -
The main use of PET may be to recognize which pts are not responding to induction chemo.
Surveillance strategy
• No RCTs to guide postop surveillance strategy and no data that shows improvement or quality of life or longevity from earlier detection of asymptomatic recurrences.
• NCCN guidelines suggest:
-Hx/Px q3-6 months for 1-3 years, then every 6 months for year 4 and 5, then annually -CBC and chemistry profile, as clinically indicated -Radiologic imaging and upper GI endoscopy, as clinically indicated -dilation for anastomotic stenosis -nutritional counseling
